Search Results
![Lasix® ONYU[1] Achieves CE Marking under EU Medical Device Regulation, Reaching a Critical Milestone Toward International Market Authorization; European Medicines Agency Confirms Eligibility for Centralized Procedure Review Based on Technical Innovation](https://mma.prnewswire.com/media/2966850/Lasix_ONYU_Infusor.jpg)
Apr 28, 2026, 08:30 ET Lasix® ONYU[1] Achieves CE Marking under EU Medical Device Regulation, Reaching a Critical Milestone Toward International Market Authorization; European Medicines Agency Confirms Eligibility for Centralized Procedure Review Based on Technical Innovation
Pharmacy. The pharmaceutical component of Lasix ONYU is a novel, high-concentration formulation of the diuretic furosemide, at 30 mg/mL. It comes in a pre-filled glass cartridge containing 80 mg of furosemide in 2.67 mL. The Lasix ONYU Infusor consists of two main parts: the Reusable Unit and the Disposable
More news about: SQ Innovation
Apr 28, 2026, 08:23 ET PRE Security Awarded U.S. Patent for Breakthrough AI Technology That Transforms Cybersecurity Data Into Predictive Intelligence
stitch together dozens of tools that speak different languages. PRE Security's patented technology changes that. By transforming raw logs into unified, human-readable narratives and then converting that meaning into AI-ready signals, PRE Security enables:Cross-platform understanding
More news about: PRE Security
Apr 28, 2026, 08:15 ET Camden National Corporation Delivers Solid First Quarter 2026 Results with Net Income of $21.9 Million and Diluted EPS of $1.29
adjusted net income; adjusted diluted earnings per share; adjusted return on average assets; adjusted return on average equity; pre-tax, pre-provision income; adjusted pre-tax, pre-provision income; return on average tangible equity and adjusted return on average tangible equity; the efficiency and tangible
More news about: Camden National Corporation
Apr 28, 2026, 08:01 ET VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
related to the Animal Rule; the company's future development of Entolimod or Entolasta; changes to the company's business strategy; timing and success of pre-clinical and clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commercialize
More news about: Valion Bio, Inc.
Apr 28, 2026, 08:00 ET Trumid Expands AI Push with Launch of Trumid Smart Voice™
investment, embedding intelligence directly into the platformThe new functionality enables users to convert unstructured conversations into pre-filled trade tickets, automatically extracting key details to support accurate booking and processing. By combining automation with human oversight,
More news about: Trumid
Apr 28, 2026, 08:00 ET Gryphon AI Unveils 1H 2026 Strategic Product Launch, Redefining Contact Compliance as a Unified GRC Control Layer
regulations across SMS, text, email, pre-recorded, and autonomous outreach, ensuring organizations stay ahead of regulatory shifts without manual intervention.Gryphon ONE for Genesys – A native integration for Genesys Cloud Outbound that enables rapid pre-interaction compliance certification,
More news about: Gryphon AI
Apr 28, 2026, 07:45 ET Commvault Announces Fourth Quarter Fiscal 2026 Financial Results
amount of GAAP pre-tax income. For the same reason as the GAAP tax rates, the estimated cash tax rates in recent fiscal years are not meaningful percentages. Commvault defines its cash tax rate as the total amount of cash income taxes payable for the fiscal year divided by consolidated GAAP pre-tax income.
More news about: COMMVAULT
Apr 28, 2026, 07:30 ET Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
agreement from the EMA on the key design components, the second, confirmatory study, called FLASH2, has demonstrated a good safety profile in the pre-specific safety evaluations by the Data Monitoring Committee. This study is a randomized, double-blind, placebo-controlled, multicenter study that replicates
More news about: SOLIGENIX, INC.
Apr 28, 2026, 07:13 ET Bioretec Ltd adjusts the terms and conditions of its stock option programs due to the completed rights issue
programs, if Bioretec resolves, prior to the share subscriptions under each option program taking place, to issue new shares in accordance with the pre-emptive right of the shareholders, the holders of option rights shall be treated equally with the shareholders of the Company. Under the terms and conditions
More news about: Bioretec
Apr 28, 2026, 07:06 ET Bioretec Ltd adjusts the terms and conditions of its stock option programs due to the completed rights issue
programs, if Bioretec resolves, prior to the share subscriptions under each option program taking place, to issue new shares in accordance with the pre-emptive right of the shareholders, the holders of option rights shall be treated equally with the shareholders of the Company. Under the terms and conditions
More news about: Bioretec
Apr 28, 2026, 07:03 ET WILLIAM RAVEIS UNVEILS RAVEIS365+ PLATFORM: STRATEGICALLY INVESTING FOR THE LONG TERM
hand", says Raveis. "Raveis365+ is their first-mover advantage that sets them apart".For the Seller. Speeds the process, from pre-listing to closing table, along with targeted digital marketing for Just Listed, Open House launches, and Broker to Broker alerts attracting the widest
More news about: William Raveis
Apr 28, 2026, 07:00 ET NG ENERGY ANNOUNCES SIGNIFICANT NEW GAS DISCOVERY IN SINU-9 BLOCK IN COLOMBIA
formations: the shallower Porquero and the deeper Pre-CDO–San Cayetano intervals, with a net pay of 149 ft and 103 ft, respectively.The Hechicero-1X well has been completed to initially enable selective production from five CDO intervals, as well as from the Pre-CDO–San Cayetano interval. Initial well tests
More news about: NG Energy International Corp.
Apr 28, 2026, 07:00 ET Stepan Reports First Quarter 2026 Results
was a $41.4 million loss versus $19.7 million of income in the prior year. The current year loss resulted from a previously announced $65.4 million pre-tax restructuring charge. Adjusted net income(1) was $10.3 million, down 47% versus the prior year, largely due to lower Surfactant earnings
More news about: Stepan Company
Apr 28, 2026, 07:00 ET Triquetra Health Launches BioActive Vitamin B6™--First Tri-Cofactor B6 System with P-5-P, Riboflavin, and Albion® Magnesium
supplement company specializing in evidence-based formulation, today announced the launch of BioActive Vitamin B6™, The Complete B6 System combining pre-activated P-5-P coenzyme with the enzymatic cofactors required for sustained B6 metabolism. Available now on Amazon in two therapeutic potencies—25mg
More news about: Triquetra Health LLC
Apr 28, 2026, 07:00 ET Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
Convention & Exhibit CenterSession: Poster ReceptionPresentation ID: 2471Poster Presentation: MSH3 Pre-mRNA Splice Modulation in the Treatment of Repeat Expansion DisordersDate: Wednesday, May 13Time: 5:00 - 6:30 PMLocation:
More news about: Ascidian Therapeutics
Apr 28, 2026, 07:00 ET The Sherwin-Williams Company Reports 2026 First Quarter Financial Results
Pre-TaxTax
More news about: The Sherwin-Williams Company
Apr 28, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
AAV-Pdx1/MafA Reverses Hyperglycemia in a Preclinical Model of Type 2 Diabetes"Abstract ID: 2419Topic: Gene-Based Therapies in Pre-Clinical Models of Genetic DiseasePoster Presentation Date: Wednesday, May 13, 2026Poster Presentation Time: 5-6:30 p.m.
More news about: Genprex, Inc.
Apr 28, 2026, 07:00 ET BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
aggressive and treatment-resistant cancers, and there is an urgent need for breakthrough innovation and more effective treatment options.In multiple pre-clinical models, including in-vivo GBM models, GLIX1 demonstrated potent anti-tumor activity, excellent blood-brain-barrier penetration, and a
More news about: BioLineRx Ltd.; Hemispherian AS
Apr 28, 2026, 06:55 ET Invesco Reports Results for the Three Months Ended March 31, 2026
the excess tax benefits related to the vesting of common share-based awards. The tax benefit in the fourth quarter of 2025 was primarily due to the pre-tax loss and was further increased by the favorable impact of the reversal of reserves for uncertain tax positions due to the expiration of statutes
More news about: Invesco Ltd.
Apr 28, 2026, 06:53 ET Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets
continues to shape the global cannabis landscape by introducing new products and formats around the world. The newly expanded lineup includes dried flower, pre‑rolls and pastilles, reflecting Aurora's long‑standing focus on innovation, quality and patient choice, while driving sustainable growth internationally.
More news about: Aurora Cannabis Inc.
Apr 28, 2026, 06:30 ET GoldMining Announces Updated PEA Highlighting $1.0 Billion After-Tax NPV and 32% IRR at La Mina Project, Colombia
UnitsInitial capital expenditure (includes pre-strip)523.3
More news about: GoldMining Inc.
Apr 28, 2026, 06:30 ET Hemlo Mining Corp. Reports First Quarter 2026 Operating Results
dislocations; financing risks and access to additional capital; risks related to guidance estimates and uncertainties inherent in the preparation of pre-feasibility studies; uncertainty in estimates of production, capital, and operating costs and potential production and cost overruns; the fluctuating
More news about: Hemlo Mining Corp.
Apr 28, 2026, 06:30 ET Kimberly-Clark Announces First Quarter 2026 Results, Reaffirms 2026 Outlook
year driven primarily by favorable currency translation.Income from discontinued operations, net of income taxes was $101 million, inclusive of pre-tax separation costs of $32 million, compared to $103 million in the prior year. Adjusted income from discontinued operations was $125 million compared
More news about: Kimberly-Clark Corporation
Apr 28, 2026, 06:15 ET Legal-Bay Pre-Settlement Funding Reports New York Archdiocese at Critical Crossroads Amid Nearly 2,000 Sex Abuse Lawsuits
year.Legal-Bay is a national provider of pre-settlement funding, specializing in complex litigation cases, including sex abuse claims. The company works with plaintiffs and attorneys to provide financial support during the litigation process.To apply right now for pre settlement funding, please visit
More news about: Legal-Bay, LLC
Apr 28, 2026, 06:15 ET Artisan Chocolate Company Sweetens Labeling Operations with Epson ColorWorks
flexibility: By bringing labeling in-house, Casa Chocolates can now test new varieties and products in small batches without committing to large runs of pre-printed labels. Emily Roberts, co-owner of Casa Chocolates notes, "If ingredients change, we can easily update labels instantly." Seasonal offerings
More news about: Epson America, Inc.